This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cue Health Inc. (HLTH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cue Health Inc. (HLTH) delivered earnings and revenue surprises of 28.89% and 6.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nyxoah SA (NYXH) delivered earnings and revenue surprises of 0% and 2.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Computer Programs and Systems (CPSI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of 5.88% and 2.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Tenet Healthcare (THC) Q4 Earnings Beat on Hospital Operations
by Zacks Equity Research
Tenet Healthcare (THC) expects net operating revenues to be between $19.9 billion and $20.3 billion in 2024.
Zacks.com featured highlights Lancaster Colony, On Holding, Rent the Runway, 5E Advanced Materials and Motus GI
by Zacks Equity Research
Lancaster Colony, On Holding, Rent the Runway, 5E Advanced Materials and Motus GI have been highlighted in this Screen of The Week article.
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Lancaster Colony (LANC), On Holding (ONON), Rent the Runway (RENT), 5E Advanced Materials (FEAM) and Motus GI (MOTS).
Cigna (CI) Q4 Earnings Beat on Membership Growth, Dividend Up
by Zacks Equity Research
Cigna (CI) expects adjusted revenues to register a minimum growth of 20.3% from the 2023 reported figure.
Humana (HUM) Q4 Earnings Miss on Higher Costs, '25 Target Pulled
by Zacks Equity Research
Humana (HUM) expects 2024 revenues to increase to around $113 billion.
Elevance (ELV) Q4 Earnings Beat on Premium Growth, Dividend Hiked
by Zacks Equity Research
Elevance Health (ELV) expects 2024 premium revenues to remain in line with the 2023 level.
Molina Healthcare (MOH) Up 26.9% in 6 Months: What Lies Ahead?
by Zacks Equity Research
Molina Healthcare (MOH) is likely to keep growing on the back of increases in investment income and Medicare premiums.
Why You Should Retain Elevance (ELV) Stock in Your Portfolio
by Zacks Equity Research
Elevance's (ELV) Carelon unit is expected to benefit from improving performance in the Behavioral Health business and post-acute care services.
UnitedHealth (UNH) Stock Declines 3.4% on High Medical Costs
by Zacks Equity Research
As more seniors resume elective procedures, claims rise in UnitedHealth's (UNH) Medicare Advantage business.
Elevance Health (ELV) & Verizon Partner to Bring Health Equity
by Zacks Equity Research
Elevance Health (ELV) launches a new program with an Affordable Connectivity Program offering free smartphones to eligible members.
Brookdale (BKD) Sees Growth in December 2023 Occupancy Volumes
by Zacks Equity Research
Brookdale (BKD) witnesses a continuous streak of 26 months of year-over-year increases in the weighted average occupancy level.
Why Acadia (ACHC) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is poised to gain from rising admissions and patient days.
Why Community Health (CYH) Shares Are Attracting Investors Now
by Zacks Equity Research
We expect Community Health's (CYH) occupancy rate to continue moving upward, reflecting improving utilization of its facilities and services.
Ensign (ENSG) Buys 2 Nursing Facilities in Tennessee & Nevada
by Zacks Equity Research
The acquisition deals have increased Ensign's (ENSG) portfolio to encompass 299 healthcare operations spanning 14 states.
Reasons to Retain HCA Healthcare (HCA) Stock in Your Portfolio
by Zacks Equity Research
HCA Healthcare's (HCA) improving top line, acquisition initiatives and a robust growth outlook poise the company well for growth.
Why You Should Retain Cigna (CI) Stock in Your Portfolio
by Zacks Equity Research
Cigna's (CI) strong Evernorth and Cigna Healthcare segments, growing medical membership and a positive 2023 outlook poise it well for growth.
Molina (MOH) to Pay Lower Price for California Medicare Buyout
by Zacks Equity Research
Molina Healthcare's (MOH) new price for Bright HealthCare's California Medicare business constitutes 23% of the anticipated $1.8 billion premium revenues for 2023.
Here's Why Investors Should Hold Elevance (ELV) Stock for Now
by Zacks Equity Research
Elevance's (ELV) Carelon unit will see growth due to improving performance in post-acute care services and Behavioral Health business.
Centene (CNC) Unveils its 2024 Projections: Key Takeaways
by Zacks Equity Research
Centene's (CNC) board boosts its share buyback program with a new $4 billion fund.
Cigna (CI) Adds $10B to Buyback Funds, Turns to Bolt-On Buyouts
by Zacks Equity Research
Cigna (CI) expects to maintain average annual adjusted EPS growth within 10-13% in the long term.
Evaluating Acadia Healthcare's (ACHC) Future View: Hold or Fold?
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is poised to capitalize on increasing patient days and bed capacity.
HCA Healthcare's (HCA) Houston Affiliate Acquires 11 EDs
by Zacks Equity Research
The deal helps HCA Healthcare (HCA) boost its freestanding EDs in the Houston region to 26, supplementing its existing hospital-based emergency rooms.